Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.71 |
| ▸ | GSK3B | P49841 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277815 | 0.84 | — | — | |
| SCHEMBL7646093 | 0.77 | — | — | |
| SCHEMBL15226499 | 0.74 | — | — | |
| SCHEMBL7052754 | 0.70 | — | — | |
| SCHEMBL806914 | 0.69 | — | — | |
| SCHEMBL11666359 | 0.69 | — | — | |
| SCHEMBL17581123 | 0.69 | — | — | |
| SCHEMBL1431864 | 0.69 | — | — | |
| SCHEMBL28725512 | 0.69 | CYP1A2 (0.44) | GSK3AGSK3BCYP1A2CFTRGOPC | |
| SCHEMBL232122 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349949-A1 | METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLIC MODULATORS | CLARIA PARTIKULA LLC | 2017-12-07 | — | — | US | claimed |
| US-20250281445-A1 | Method of dietary treatment for genetic and epigenetic diseases and disorders | OTT DAVID MICHAEL (US) | 2025-09-11 | — | — | US | disclosed |
| US-20220056488-A1 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF AROMATICS, 2,4-PENTADIENOATE AND 1,3-BUTADIENE | GENOMATICA INC (US) | 2022-02-24 | — | — | US | disclosed |
| US-20210275487-A1 | METHOD OF DIETARY TREATMENT FOR GENETIC AND EPIGENETIC DISEASES AND DISORDERS | OTT DAVID MICHAEL (US) | 2021-09-09 | — | — | US | disclosed |
| US-11026911-B2 | Method of dietary treatment for genetic and epigenetic diseases and disorders | OTT DAVID MICHAEL (US) | 2021-06-08 | — | — | US | disclosed |
| US-10793882-B2 | Microorganisms and methods for the biosynthesis of aromatics, 2,4-pentadienoate and 1,3-butadiene | GENOMATICA, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10583106-B2 | Method of treating cancer by oral administration of acetate composition comprising magnesium acetate, calcium acetate or ethylacetate | OTT DAVID MICHAEL (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190117610-A1 | METHOD OF DIETARY TREATMENT FOR GENETIC AND EPIGENETIC DISEASES AND DISORDERS | OTT DAVID MICHAEL (US) | 2019-04-25 | — | — | US | disclosed |
| US-9968580-B2 | Method of treating Rett syndrome by oral administration of acetate which is provided as composition comprising magnesium acetate, calcium acetate or ethylacetate | OTT DAVID MICHAEL (US) | 2018-05-15 | — | — | US | disclosed |
| EP-3312284-A2 | MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF AROMATICS, 2,4-PENTADIENOATE AND 1,3-BUTADIENE | Genomatica, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2011159658-A9 | METHODS,ASSAYS, AND KITS RELATED TO DICHLOROACETATE (DCA) | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011159658-A2 | METHODS,ASSAYS, AND KITS RELATED TO DICHLOROACETATE (DCA) | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011109874-A1 | INHIBITION OF GLUTATHIONE TRANSFERASE ZETA | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011017560-A1 | SEMI-SYNTHETIC TEREPHTHALIC ACID VIA MICROORGANISMS THAT PRODUCE MUCONIC ACID | GENOMATICA, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| EP-1523485-B1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-14 | — | — | EP | disclosed |
| US-6653331-B2 | Depleting intracellular reduced glutathione levels in vivo | PHARMACIA & UPJOHN COMPANY | 2003-11-25 | — | — | US | disclosed |
| EP-0909184-B1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | UPJOHN CO (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030109555-A1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJ0HN COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-0909184-A2 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1998000173-A2 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109555-A1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | GSTP1, GSTA2, GSTA1 | GSK3A 3876/4885GSK3B 4196/4885CYP1A2 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.